Archives
-
Tioconazole Workflows for Antifungal Research
2026-09-12
Build reproducible Tioconazole experiments around sterol-pathway biology, solvent-matched controls, and orthogonal fungal readouts. The workflow supports antifungal drug development, resistance profiling, and staged fungal infection model optimization without confusing research evidence with clinical guidance.
-
CENPI Drives Breast Cancer via Wnt/β-Catenin
2026-09-11
A 2025 study identifies centromere protein I (CENPI) as an oncogenic driver of breast cancer and connects its activity to Wnt/β-catenin signaling. By integrating patient datasets, cellular assays, xenografts, RNA sequencing, and pathway reporters, the work provides a mechanistic basis for considering CENPI as a biomarker and potential therapeutic target.
-
Live-Dead Cell Staining Kit for Translational Insight
2026-09-11
A mechanistic and translational guide to using dual Calcein-AM and Propidium Iodide staining to evaluate biomaterial cytocompatibility, drug effects, and cell-state transitions. The discussion connects viability data to findings from a multifunctional GelMA/QCS/Ca2+ hemostatic adhesive study while clarifying what live-dead assays can—and cannot—support.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-09-10
Wang and colleagues developed a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma and used transcriptomic connectivity analysis to identify Atorvastatin as a candidate treatment. In vitro and in vivo experiments supported ferroptosis induction alongside reduced HCC cell growth and migration, while also highlighting the need for further mechanistic and clinical validation.
-
QNZ (EVP4593) Workflow for NF-κB Studies
2026-09-10
QNZ (EVP4593) provides a nanomolar tool for connecting NF-κB reporter activity with TNF-α output, inflammatory phenotypes, and neuronal calcium signaling. This workflow shows how to solubilize, dose, validate, and troubleshoot the compound while using osteomyelitis findings to design—but not overstate—new inflammation experiments.
-
Netarsudil (AR-13324) for ROCK and siRNA
2026-09-09
Netarsudil (AR-13324) combines selective ROCK pathway inhibition with an emerging role in ionizable-drug nanoparticle design. This article translates its trabecular meshwork biology and siRNA codelivery potential into practical assay workflows, controls, and troubleshooting decisions.
-
Tacrolimus (FK506) at the Immune–Metabolic Interface
2026-09-09
Tacrolimus (FK506) is more than a calcineurin inhibitor: it can serve as a precise perturbation tool for separating cytokine control from metabolic-stress signaling. This article connects FK506 assay design with the AMPK–SQSTM1/p62–NRF2 feedback loop and practical immunology workflows.
-
DAPI Nuclear Stain Solution: Practical Guide
2026-09-08
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA binding dye for nuclear visualization, endpoint cell viability assessment, and selected apoptosis-related workflows. It is most appropriate for fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, rather than routine imaging of intact live cells.
-
HotStart qPCR Master Mix: Reliable Cell Assays
2026-09-08
Learn how HotStart™ Universal 2X FAST Green qPCR Master Mix (Rox), SKU K1172, supports reproducible gene expression analysis alongside cell viability, proliferation, and cytotoxicity assays. This scenario-based guide covers inhibitor tolerance, ROX normalization, melt curve analysis, protocol setup, interpretation, and practical vendor selection.
-
HotStart Universal 2X FAST Green qPCR Master Mix Workflow
2026-09-07
Build a faster, inhibitor-tolerant RT-qPCR workflow for RCC gene expression analysis using ROX normalization and melt-curve verification. The approach translates albiflorin study findings into practical assays for MMP9, FGF2, EGFR, treatment response, and signaling validation.
-
AO/PI Double Staining Kit: 5 Lab Scenarios
2026-09-07
This scenario-based guide explains how AO/PI Double Staining Kit SKU K2238 supports practical cell viability, apoptosis detection, and necrosis detection workflows. It covers interpretation, organoid compatibility, protocol controls, storage, and vendor-selection considerations for reproducible fluorescent cell staining.
-
Ferroptosis Signature Identifies Atorvastatin in HCC
2026-09-05
This 2025 study combines a four-gene ferroptosis-related prognostic signature with Connectivity Map screening to identify Atorvastatin as a candidate agent for hepatocellular carcinoma. Its computational results and in vitro and in vivo validation suggest that Atorvastatin can promote ferroptosis while limiting HCC cell growth and migration, although clinical translation remains un established.
-
Ferroptosis Signature and Atorvastatin in HCC
2026-09-04
A 2025 study developed a four-gene ferroptosis-related prognostic signature for hepatocellular carcinoma and used Connectivity Map screening to identify Atorvastatin as a candidate therapeutic compound. In vitro and in vivo experiments indicated that Atorvastatin induces ferroptosis-associated effects while suppressing HCC cell growth and migration, providing a basis for further validation rather than immediate clinical translation.
-
Live-Dead Cell Staining Kit in Mechanistic Assays
2026-09-04
The Live-Dead Cell Staining Kit becomes more informative when interpreted as a mechanistic endpoint rather than a simple viability percentage. This guide explains how Calcein-AM and Propidium Iodide staining can strengthen flow cytometry, microscopy, drug cytotoxicity, and biomaterial studies while avoiding overinterpretation.
-
Ionizing Radiation and Altered Neural Differentiation
2026-09-03
Eom et al. showed that ionizing radiation does more than reduce neural stem-cell survival: in C17.2 cells, it promotes an altered neuronal differentiation program characterized by increased neurite outgrowth, neuronal markers, and glutamate-receptor expression. The study links this response to coordinated PI3K-STAT3-mGluR1 and PI3K-p53 signaling, providing a mechanistic framework for radiation-associated neural dysfunction.